pembrolizumab
merck
['melanoma', 'lcsm,(-blcsm)', 'thoracic', 'pembro']
s1801: neo- vs. adjuvant pembrolizumab for stage iii-iv melanoma by . striking efs benefits by neoadjuvant! simple but highly important clinical question. expect that it is not limited to melanoma. direct comparison is needed in thoracic oncology. #lcsm #esmo22 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC